Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 29767-20-2 | Product Number: T3109
Teniposide
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 20MG |
$101.00
|
1 | Contact Us | ≥60 |
|
| 100MG |
$323.00
|
1 | Contact Us | 17 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | T3109 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__3__2H__3__2O__1__3S = 656.66 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 20MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 29767-20-2 |
| Reaxys Registry Number | 7108452 |
| PubChem Substance ID | 253662241 |
| Merck Index (14) | 9145 |
| MDL Number | MFCD00866516 |
Specifications
| Appearance | White to Almost white powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Specific rotation [a]20/D | -107.0 to -115.0 deg(C=1, CHCl3:MeOH=9:1) |
Properties (reference)
| Melting Point | 247 °C(dec.) |
| Specific Rotation | -111° (C=1,CHCl3:MeOH=9:1) |
| Maximum Absorption Wavelength | 283(MeOH) nm |
| Solubility in water | Insoluble |
| Degree of solubility in water | 5.9 mg/l 25 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. H371 : May cause damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H341 : Suspected of causing genetic defects. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P405 : Store locked up. |
Related Laws:
| RTECS# | KC0180000 |
Transport Information:
| HS Number | 2938.90.0000 |
Application
Adeno-associated virus vector transduction enhancer
Teniposide exhibits enhancement of adeno-associated virus transduction.1)
References
- 1) Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens
Application
Teniposide: An Inhibitor of Topoisomerase II
Teniposide (VM26) and etoposide (VP16-213) [E0675] are semisynthetic derivatives of podophyllotoxin [P1771], an alkaloid. Teniposide and teniposide are an inhibitor of topoisomerase II such as doxorubicin [D4193], daunorubicin [D4532]. Topoisomerase II is an enzyme essential for DNA replication, chromosome condensation and chromosome segregation. Topoisomerase II inhibitors are potent inducers of double strand breaks in DNA, and can cause arrest in the cell cycle at the G2 stage. Therefore, topoisomerase II inhibitors are the most widely used anti-cancer agents. Teniposide is used for the treatment of acute lymphocytic leukemia (ALL). (The product is for research purpose only.)
References
- The podophyllotoxin derivatives VP16-213 and VM26 (a review)
- The clinical pharmacology of etoposide and teniposide (a review)
- Clinical applications of anticancer drugs targeted to topoisomerase II
- Podophyllotoxin (a review)
- Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.